These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 2483899)

  • 1. [Evaluation of the immune status against the viruses of measles, mumps, rubella, and hepatitis B in a cohort of students from the province of Como].
    Fraizzoli G; Sesana BM
    Ann Ig; 1989; 1(5):1163-71. PubMed ID: 2483899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
    Buxbaum S; Doerr HW; Allwinn R
    Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Susceptibility to measles, rubella and parotitis in young adults].
    Bayas JM; Vilella A; Vidal J; Nebot X; Carbó JM; Navarro G; Prat A; Asenjo MA; Salleras L
    Med Clin (Barc); 1996 Apr; 106(15):561-4. PubMed ID: 8656753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunity coverage against measles, rubella and parotiditis viruses in a juvenile population in Leon, Spain].
    Suárez J; Castañeda MR; Gutiérrez CB; Rodríguez Barbosa JI; Tascón RI; Rodríguez Ferri EF
    Med Clin (Barc); 1993 Oct; 101(13):484-7. PubMed ID: 8231381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000-2004.
    Eick AA; Hu Z; Wang Z; Nevin RL
    Vaccine; 2008 Jan; 26(4):494-501. PubMed ID: 18155326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The prevalence of measles, rubella, mumps and chickenpox antibodies in a population of health care workers].
    Oliveira J; da Cunha S; Côrte-Real R; Sampaio L; Dais N; Meliço-Silvestre A
    Acta Med Port; 1995 Apr; 8(4):206-16. PubMed ID: 7625214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibody titers against measles, rubella, mumps and varicella-zoster viruses in medical students].
    Yoshida N; Tsumura N; Toyomasu K; Sagawa K
    Sangyo Eiseigaku Zasshi; 2007 Jan; 49(1):21-6. PubMed ID: 17303935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Seroprotection against hepatitis A, measles, rubella, and parotiditis in an urban school population].
    Gil A; González A; Dal-Ré R; Aguilar L; Rey Calero J
    Med Clin (Barc); 1991 May; 96(18):681-4. PubMed ID: 1649358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD.
    Naganuma M; Nagahori M; Fujii T; Morio J; Saito E; Watanabe M
    Inflamm Bowel Dis; 2013 Feb; 19(2):418-22. PubMed ID: 22605673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
    J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rubella susceptibility predicts measles susceptibility: implications for postpartum immunization.
    Libman MD; Behr MA; Martel N; Ward BJ
    Clin Infect Dis; 2000 Dec; 31(6):1501-3. PubMed ID: 11096023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte blast transformation response of seropositive and seronegative subjects to herpes simplex, rubella, mumps and measles virus antigens.
    Ilonen J
    Acta Pathol Microbiol Scand C; 1979 Apr; 87C(2):151-7. PubMed ID: 220840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M; Berger R; Just V
    Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.